Applied Molecular Evolution, Inc. to Present at 23rd Annual SG Cowen Healthcare Conference.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--March 17, 2003 Applied Molecular Evolution, Inc. (AME See AIT. ) (Nasdaq:AMEV AMEV Armored Medical Evacuation Vehicle ) announced today that it will present at the SG Cowen 23rd Annual Healthcare Conference at 8:00 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy on March 18, 2003. The conference is being held at the Boston Marriott Copley Place Copley Place is an enclosed shopping mall located in the Back Bay section of Boston, Massachusetts. It is part of a complex that includes office buildings, two hotels, and a parking garage. Hotel. AME's presentation will be webcast live and will be available via archive following the conference. The presentation can be accessed at www.AME.biz. About Applied Molecular Evolution Applied Molecular Evolution, Inc. (AME) is a leader in applying directed molecular evolution to improve healthcare by optimizing and developing human biotherapeutics. Directed molecular evolution is a process for optimizing genes and proteins for specific commercial purposes. Since its inception, AME's principal focus has been on applying its proprietary AMEsystem(TM) technology platform to human biotherapeutics, the largest market for directed molecular evolution. Biotherapeutics, or biopharmaceuticals, are protein pharmaceuticals such as antibodies, cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , hormones and enzymes. AME uses its proprietary technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. For more information, please visit www.AME.biz. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including uncertainties related to product development, uncertainties related to the need for regulatory or other government approvals, dependence on proprietary technology, uncertainty of market acceptance of the Company's products, uncertainties related to business opportunities, the receipt of future payments, including royalties, the continuation of customer relationships and other risks cited in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002, and other SEC Filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion